vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and ESCO TECHNOLOGIES INC (ESE). Click either name above to swap in a different company.
ESCO TECHNOLOGIES INC is the larger business by last-quarter revenue ($289.7M vs $196.0M, roughly 1.5× Axsome Therapeutics, Inc.). ESCO TECHNOLOGIES INC runs the higher net margin — 9.9% vs -14.6%, a 24.5% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 17.3%). ESCO TECHNOLOGIES INC produced more free cash flow last quarter ($63.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 7.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Esco is a Singaporean brand that develops, manufactures, and sells products and services for laboratories.
AXSM vs ESE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $289.7M |
| Net Profit | $-28.6M | $28.7M |
| Gross Margin | — | 41.4% |
| Operating Margin | -13.8% | 13.2% |
| Net Margin | -14.6% | 9.9% |
| Revenue YoY | 65.0% | 17.3% |
| Net Profit YoY | 61.9% | 22.2% |
| EPS (diluted) | $-0.55 | $1.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $289.7M | ||
| Q3 25 | $171.0M | $286.5M | ||
| Q2 25 | $150.0M | $296.3M | ||
| Q1 25 | $121.5M | $265.5M | ||
| Q4 24 | $118.8M | $247.0M | ||
| Q3 24 | $104.8M | $298.5M | ||
| Q2 24 | $87.2M | $260.8M | ||
| Q1 24 | $75.0M | $249.1M |
| Q4 25 | $-28.6M | $28.7M | ||
| Q3 25 | $-47.2M | $218.7M | ||
| Q2 25 | $-48.0M | $26.1M | ||
| Q1 25 | $-59.4M | $31.0M | ||
| Q4 24 | $-74.9M | $23.5M | ||
| Q3 24 | $-64.6M | $34.3M | ||
| Q2 24 | $-79.3M | $29.2M | ||
| Q1 24 | $-68.4M | $23.2M |
| Q4 25 | — | 41.4% | ||
| Q3 25 | — | 45.9% | ||
| Q2 25 | — | 41.2% | ||
| Q1 25 | — | 41.1% | ||
| Q4 24 | — | 39.8% | ||
| Q3 24 | — | 40.1% | ||
| Q2 24 | — | 39.6% | ||
| Q1 24 | — | 38.8% |
| Q4 25 | -13.8% | 13.2% | ||
| Q3 25 | -27.0% | 17.2% | ||
| Q2 25 | -24.5% | 11.2% | ||
| Q1 25 | -46.9% | 15.3% | ||
| Q4 24 | -61.1% | 11.4% | ||
| Q3 24 | -59.8% | 14.8% | ||
| Q2 24 | -89.5% | 14.3% | ||
| Q1 24 | -89.7% | 11.7% |
| Q4 25 | -14.6% | 9.9% | ||
| Q3 25 | -27.6% | 76.3% | ||
| Q2 25 | -32.0% | 8.8% | ||
| Q1 25 | -48.9% | 11.7% | ||
| Q4 24 | -63.1% | 9.5% | ||
| Q3 24 | -61.7% | 11.5% | ||
| Q2 24 | -91.0% | 11.2% | ||
| Q1 24 | -91.1% | 9.3% |
| Q4 25 | $-0.55 | $1.11 | ||
| Q3 25 | $-0.94 | $8.43 | ||
| Q2 25 | $-0.97 | $1.01 | ||
| Q1 25 | $-1.22 | $1.20 | ||
| Q4 24 | $-1.54 | $0.91 | ||
| Q3 24 | $-1.34 | $1.32 | ||
| Q2 24 | $-1.67 | $1.13 | ||
| Q1 24 | $-1.44 | $0.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $103.8M |
| Total DebtLower is stronger | — | $145.5M |
| Stockholders' EquityBook value | $88.3M | $1.6B |
| Total Assets | $689.8M | $2.4B |
| Debt / EquityLower = less leverage | — | 0.09× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $103.8M | ||
| Q3 25 | $325.3M | $101.3M | ||
| Q2 25 | $303.0M | $78.7M | ||
| Q1 25 | $300.9M | $57.4M | ||
| Q4 24 | $315.4M | $71.3M | ||
| Q3 24 | $327.3M | $66.0M | ||
| Q2 24 | $315.7M | $63.0M | ||
| Q1 24 | $331.4M | $59.4M |
| Q4 25 | — | $145.5M | ||
| Q3 25 | — | $186.0M | ||
| Q2 25 | — | $525.0M | ||
| Q1 25 | — | $88.0M | ||
| Q4 24 | — | $112.0M | ||
| Q3 24 | — | $122.0M | ||
| Q2 24 | — | $173.0M | ||
| Q1 24 | — | $191.0M |
| Q4 25 | $88.3M | $1.6B | ||
| Q3 25 | $73.7M | $1.5B | ||
| Q2 25 | $73.1M | $1.3B | ||
| Q1 25 | $53.2M | $1.3B | ||
| Q4 24 | $57.0M | $1.2B | ||
| Q3 24 | $92.9M | $1.2B | ||
| Q2 24 | $102.9M | $1.2B | ||
| Q1 24 | $144.0M | $1.2B |
| Q4 25 | $689.8M | $2.4B | ||
| Q3 25 | $669.3M | $2.4B | ||
| Q2 25 | $639.8M | $2.5B | ||
| Q1 25 | $596.7M | $1.8B | ||
| Q4 24 | $568.5M | $1.8B | ||
| Q3 24 | $561.5M | $1.8B | ||
| Q2 24 | $548.2M | $1.8B | ||
| Q1 24 | $545.7M | $1.8B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.09× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $68.9M |
| Free Cash FlowOCF − Capex | $-18.7M | $63.0M |
| FCF MarginFCF / Revenue | -9.6% | 21.7% |
| Capex IntensityCapex / Revenue | 0.0% | 2.0% |
| Cash ConversionOCF / Net Profit | — | 2.40× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $239.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $68.9M | ||
| Q3 25 | $1.0M | $109.9M | ||
| Q2 25 | $-32.4M | $73.7M | ||
| Q1 25 | $-43.4M | $24.1M | ||
| Q4 24 | $-26.2M | $34.2M | ||
| Q3 24 | $-18.6M | $72.1M | ||
| Q2 24 | $-30.1M | $36.2M | ||
| Q1 24 | $-53.5M | $10.5M |
| Q4 25 | $-18.7M | $63.0M | ||
| Q3 25 | $988.0K | $97.8M | ||
| Q2 25 | $-32.4M | $64.9M | ||
| Q1 25 | $-43.7M | $14.0M | ||
| Q4 24 | $-26.2M | $29.0M | ||
| Q3 24 | $-18.7M | $60.9M | ||
| Q2 24 | $-30.2M | $27.6M | ||
| Q1 24 | $-53.6M | $2.0M |
| Q4 25 | -9.6% | 21.7% | ||
| Q3 25 | 0.6% | 34.1% | ||
| Q2 25 | -21.6% | 21.9% | ||
| Q1 25 | -36.0% | 5.3% | ||
| Q4 24 | -22.1% | 11.7% | ||
| Q3 24 | -17.9% | 20.4% | ||
| Q2 24 | -34.6% | 10.6% | ||
| Q1 24 | -71.4% | 0.8% |
| Q4 25 | 0.0% | 2.0% | ||
| Q3 25 | 0.0% | 4.2% | ||
| Q2 25 | 0.0% | 3.0% | ||
| Q1 25 | 0.3% | 3.8% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.1% | 3.8% | ||
| Q2 24 | 0.1% | 3.3% | ||
| Q1 24 | 0.1% | 3.4% |
| Q4 25 | — | 2.40× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 2.83× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | 2.10× | ||
| Q2 24 | — | 1.24× | ||
| Q1 24 | — | 0.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
